Xalud Therapeutics is a biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system. Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10 to addresses pathologic inflammation and pain.
Location: United States, New York
Member count: 11-50
Total raised: $30M
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | PBM Capita... | pbmcap.com |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 24.08.2021 | Series C | $30M | - | - |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 31.08.2021 | Digital he... | Headspace's resilience brand a... | - | Kristin Ka... | vator.tv/n... |
| 25.08.2021 | Daily fund... | Bridge to Life raised $56M; Co... | - | Kristin Ka... | vator.tv/n... |
| 24.08.2021 | Xalud Ther... | Xalud Therapeutics, a clinical... | - | - | marketscre... |